Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. John K. A. Prendergast Ph.D. | Executive Chairman of the Board | 380.55k | -- | 1954 |
| Mr. James Hamilton-Bray Graham GAICD | CEO, MD & Executive Director | 834.51k | -- | -- |
| Ms. Michele Keryn Dilizia BA (Journ), BSc (Med Sci) | Chief Scientific Director & Executive Director | 530.84k | -- | -- |
| Dr. Justin Ward | Principal Quality Chemist & Executive Director | 318.53k | -- | -- |
| Mr. Arthur Kollaras | Principal Engineer & Head of Manufacturing | 564.01k | -- | -- |
| Dr. Alan W. Dunton B.Sc., M.D. | Chief Medical Advisor & Independent Non Executive Director | 75k | -- | 1954 |
| Mr. Justin Reynolds | Chief Financial Officer | -- | -- | -- |
| Mr. Daniel Astudillo B.A., B.Com., M.B.A. | Head of Marketing | -- | -- | -- |
| Ms. Maggie Niewidok | Company Secretary | -- | -- | -- |
Recce Pharmaceuticals Ltd
- Sector:
- Healthcare
- Industry: Biotechnology
Description
Recce Pharmaceuticals Ltd, discovers, develops, and commercializes synthetic antiinfectives in Australia, the United Kingdom, and the United States. Its lead candidate is RECCE 327 (R327) for the treatment of blood infections and sepsis derived from E. coli and S. aureus bacteria, including their superbug forms. The company also develops RECCE 529, a synthetic anti-infective for viral infections; and RECCE 435, a synthetic polymer antibiotic formulated for oral use. In addition, its product pipeline comprises R327 Intravenous, which is in Phase I/II clinical trial for the treatment of urinary tract infections/urosepsis rapid infusion; and R327 Topical Gel, which is Phase II clinical trial for the treatment of acute bacterial skin and skin structure infections, as well as is in Phase I/II clinical trials for topical wound infections and diabetic foot infections. Recce Pharmaceuticals has strategic partnership with Murdoch Children's Research Institute for development of the Neisseria gonorrhoeae, Mycobacterium abscessus, and Escherichia coli clinical trials. The company was formerly known as Recce Limited and changed its name to Recce Pharmaceuticals Ltd in November 2017. Recce Pharmaceuticals Ltd was incorporated in 2007 and is headquartered in Sydney, Australia.
Corporate Governance
Upcoming Events
February 27, 2025 at 9:50 PM UTC
Recce Pharmaceuticals Ltd Earnings Date
Recent Events
Recent Events Information Not Available